<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nid</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология и диализ</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology and Dialysis</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1680-4422</issn><issn pub-type="epub">2618-9801</issn><publisher><publisher-name>Российское диализное общество</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">nid-3774</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ШКОЛА НЕФРОЛОГА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EDUCATIONAL MATERIALS</subject></subj-group></article-categories><title-group><article-title>Сердечно-сосудистые последствия почечной анемии и терапия эритропоэтином</article-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular consequences of renal anaemia and erythropoietin therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кай-Уве</surname><given-names>Екард</given-names></name><name name-style="western" xml:lang="en"><surname>Kai-Uwe</surname><given-names>Eckardt</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Отделение нефрологии и интенсивной медицины, Шарите, Университет Гумбольдта, Берлин, Германия</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2000</year></pub-date><pub-date pub-type="epub"><day>28</day><month>06</month><year>2025</year></pub-date><volume>2</volume><issue>3</issue><fpage>181</fpage><lpage>188</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кай-Уве Е., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Кай-Уве Е.</copyright-holder><copyright-holder xml:lang="en">Kai-Uwe E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephro.ru/jour/article/view/3774">https://journal.nephro.ru/jour/article/view/3774</self-uri><abstract><p>История болезни 1 Больной 37 лет. В возрасте 30 лет впервые была диагностирована хроническая почечная недостаточность (ХПН). Биопсия почки не производилась. 7 лет спустя развилась терминальная ХПН (ТХПН), и был начат программный гемодиализ (ГД) в режиме 3 раза в неделю. До начала ГД имела место умеренная артериальная гипертония. После начала диализной терапии она уменьшилась и далее хорошо контролировалась малыми дозами метопролола. Гемоглобин крови (Нb) к началу ГД составлял 7-7,5 г/дл, в связи с чем через 4 мес. после начала диализа была начата терапия рекомбинантным эритропоэтином (Эпо). В результате уровень Нb быстро повысился до 10 г/дл и затем постепенно нормализовался. Доза Эпо составляет в настоящее время 6000 МЕ в неделю. Пациент часто путешествует, получая ГД в других диализных центрах. Во время путешествий Эпо-терапия, как правило, прерывается, ибо, по мнению большинства врачей этих центров, целевой Нb должен быть более низким. Как следствие, уровень Нb у пациента значительно и необычным образом варьирует. Сам пациент отмечает, что при снижении Нb ниже 12 г/дл его трудоспособность и физическая активность снижаются, становясь субоптимальными. Тем не менее, он вполне трудоспособен, и будучи кандидатом наук и занимаясь интеллектуальной деятельностью, работает полный рабочий день. Ангинозные приступы и одышка его не беспокоят. По данным эхокардиограммы, выполненной через 7 лет после начала ГД, размеры левого желудочка, толщина перегородки и задней стенки левого желудочка не изменены, дисфункция миокарда отсутствует. ** Публикуется по согласованию с автором и с разрешения Oxford University Press. ** Перевод Н.А. Томилиной, А.С. Бирюковой</p></abstract><kwd-group xml:lang="ru"><kwd>анемия</kwd><kwd>кардиальная ишемия</kwd><kwd>уремическая кардиомиопатия</kwd><kwd>эритропоэтин</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Pastan S., Bailey J. Dialysis therapy. N Engi J Med 1998; 338: 1428-1437.</mixed-citation><mixed-citation xml:lang="en">Pastan S., Bailey J. Dialysis therapy. N Engi J Med 1998; 338: 1428-1437.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mall G., Rambausek M., Neumeister A. et al. Myocardial interstitial fibrosis in experimental uremia-implications for cardiac compliance. Kidney Int 1988; 33: 804-811.</mixed-citation><mixed-citation xml:lang="en">Mall G., Rambausek M., Neumeister A. et al. Myocardial interstitial fibrosis in experimental uremia-implications for cardiac compliance. Kidney Int 1988; 33: 804-811.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mall G., Huther W., Schneider J. et al. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990; 5: 39-44.</mixed-citation><mixed-citation xml:lang="en">Mall G., Huther W., Schneider J. et al. Diffuse intermyocardiocytic fibrosis in uraemic patients. Nephrol Dial Transplant 1990; 5: 39-44.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ikram H., Lynn K.L., Bailey R.R. et al. Cardiovascular changes in chronic hemodialysis patients. Kidney Int 1983; 24: 371-376.</mixed-citation><mixed-citation xml:lang="en">Ikram H., Lynn K.L., Bailey R.R. et al. Cardiovascular changes in chronic hemodialysis patients. Kidney Int 1983; 24: 371-376.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Rostand S.G., Kirk K.A., Rutsky E.A. Dialysis-associated ischemic heart disease: Insights from coronary angiography. Kidney Int 1984; 25: 653-659.</mixed-citation><mixed-citation xml:lang="en">Rostand S.G., Kirk K.A., Rutsky E.A. Dialysis-associated ischemic heart disease: Insights from coronary angiography. Kidney Int 1984; 25: 653-659.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Amann К., Wiest G., Zimmer G. et al. Reduced capillary density in the myocardium of uremic rats-a stereological study. Kidney Int 1992; 42: 1079-1085.</mixed-citation><mixed-citation xml:lang="en">Amann К., Wiest G., Zimmer G. et al. Reduced capillary density in the myocardium of uremic rats-a stereological study. Kidney Int 1992; 42: 1079-1085.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Raine A.E.G., Seymour A.-M.L., Roberts A.F.C. et al. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 1993; 92: 2934-2940.</mixed-citation><mixed-citation xml:lang="en">Raine A.E.G., Seymour A.-M.L., Roberts A.F.C. et al. Impairment of cardiac function and energetics in experimental renal failure. J Clin Invest 1993; 92: 2934-2940.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Foley R.N., Parfrey P.S., Harnett J.D. et al. Clinical and echocardio-graphic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.</mixed-citation><mixed-citation xml:lang="en">Foley R.N., Parfrey P.S., Harnett J.D. et al. Clinical and echocardio-graphic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Greaves S.C., Gamble G.D., Collins J.F. et al. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kid Dis 1994; 24: 768-776.</mixed-citation><mixed-citation xml:lang="en">Greaves S.C., Gamble G.D., Collins J.F. et al. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kid Dis 1994; 24: 768-776.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Parfrey P.S., Foley R.N., Harnett J.D. et al. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 1996; 11: 1277-1285.</mixed-citation><mixed-citation xml:lang="en">Parfrey P.S., Foley R.N., Harnett J.D. et al. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 1996; 11: 1277-1285.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Silberberg J.S., Barre Р.Е., Prichard S.S. et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1988; 36: 286-290.</mixed-citation><mixed-citation xml:lang="en">Silberberg J.S., Barre Р.Е., Prichard S.S. et al. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1988; 36: 286-290.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Herzog C.A., Ma J.Z., Collins A.J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engi J Med 1998; 339: 799-805.</mixed-citation><mixed-citation xml:lang="en">Herzog C.A., Ma J.Z., Collins A.J. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engi J Med 1998; 339: 799-805.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Renal Data System. USRDS 1997 annual data report Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases 1997; D1-D51.</mixed-citation><mixed-citation xml:lang="en">Renal Data System. USRDS 1997 annual data report Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases 1997; D1-D51.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Neill W.A., Oxendine J.M., Moore S.C. Acute and chronic cardiovascular adjustments to induced anemia in dogs. Am J Physiol 1969; 217: 710-714.</mixed-citation><mixed-citation xml:lang="en">Neill W.A., Oxendine J.M., Moore S.C. Acute and chronic cardiovascular adjustments to induced anemia in dogs. Am J Physiol 1969; 217: 710-714.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Schwartz S., Frantz R.A., Shoemaker W.C. Sequential hemodynamic and oxygen transport responses in hypovolemia, anemia, and hypoxia. Am J Physiol 1981; 241: H864-H871.</mixed-citation><mixed-citation xml:lang="en">Schwartz S., Frantz R.A., Shoemaker W.C. Sequential hemodynamic and oxygen transport responses in hypovolemia, anemia, and hypoxia. Am J Physiol 1981; 241: H864-H871.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Roy S.B., Bhatia M.L., Mathur V.S. et al. Hemodynamic effects of chronic severe anemia. Circulation 1963; 28: 346-356.</mixed-citation><mixed-citation xml:lang="en">Roy S.B., Bhatia M.L., Mathur V.S. et al. Hemodynamic effects of chronic severe anemia. Circulation 1963; 28: 346-356.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Duke M., Abelmann W.H. The hemodynamic response to chronic anemia. Circulation 1969; 39: 503-515.</mixed-citation><mixed-citation xml:lang="en">Duke M., Abelmann W.H. The hemodynamic response to chronic anemia. Circulation 1969; 39: 503-515.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Olivetti G., Quaini F., Lagrasta С. et al. Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. Am J Pathol 1992; 141: 227-239.</mixed-citation><mixed-citation xml:lang="en">Olivetti G., Quaini F., Lagrasta С. et al. Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. Am J Pathol 1992; 141: 227-239.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">London G.M., Fabiani F., Marchais S.J. et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 1987; 31: 973-980.</mixed-citation><mixed-citation xml:lang="en">London G.M., Fabiani F., Marchais S.J. et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int 1987; 31: 973-980.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Levin A., Singer J., Thompson C.R. et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kid Dis 1996; 27: 347-354.</mixed-citation><mixed-citation xml:lang="en">Levin A., Singer J., Thompson C.R. et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kid Dis 1996; 27: 347-354.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Foley R.N., Parfrey P.S., Harnett J.D. et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kid Dis 1996; 28: 53-61.</mixed-citation><mixed-citation xml:lang="en">Foley R.N., Parfrey P.S., Harnett J.D. et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kid Dis 1996; 28: 53-61.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Madore F., Lowrie E.G., Brugnara С. et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. JASN 1997; 8: 1921-1929.</mixed-citation><mixed-citation xml:lang="en">Madore F., Lowrie E.G., Brugnara С. et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. JASN 1997; 8: 1921-1929.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Wizemann V., Kaufmann J., Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992; 62: 161-165.</mixed-citation><mixed-citation xml:lang="en">Wizemann V., Kaufmann J., Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992; 62: 161-165.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Macdougall L.С., Lewis N.P., Saunders M.J. et al. Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet 1990; 335: 489-493.</mixed-citation><mixed-citation xml:lang="en">Macdougall L.С., Lewis N.P., Saunders M.J. et al. Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet 1990; 335: 489-493.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Neff M.S., Kwan E.K., Persoff M. et al. Hemodynamics of uremic anemia. Circulation 1971; 43: 876-883.</mixed-citation><mixed-citation xml:lang="en">Neff M.S., Kwan E.K., Persoff M. et al. Hemodynamics of uremic anemia. Circulation 1971; 43: 876-883.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Sikole A., Polenakovic M., Spirovska V. et al. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 1993; 17: 977-984.</mixed-citation><mixed-citation xml:lang="en">Sikole A., Polenakovic M., Spirovska V. et al. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 1993; 17: 977-984.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Low-Friedrich I., Grtltzmacher P., Marz W. et al. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 1991; 11: 54-60.</mixed-citation><mixed-citation xml:lang="en">Low-Friedrich I., Grtltzmacher P., Marz W. et al. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 1991; 11: 54-60.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Cannella G., LaCanna G., Sandrini M. et al. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol 1990; 34: 272-282.</mixed-citation><mixed-citation xml:lang="en">Cannella G., LaCanna G., Sandrini M. et al. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients. Clin Nephrol 1990; 34: 272-282.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">London G.M., Zins В., Pannier В. et al. Vascular changes in hemodialysis patients in response to reombinant human erythropoietin. Kidney Int 1989; 36: 878-882.</mixed-citation><mixed-citation xml:lang="en">London G.M., Zins В., Pannier В. et al. Vascular changes in hemodialysis patients in response to reombinant human erythropoietin. Kidney Int 1989; 36: 878-882.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Low I., Grutzmacher P., Bergmann M. et al. Echocardiographic. findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol 1988; 31: 26-30.</mixed-citation><mixed-citation xml:lang="en">Low I., Grutzmacher P., Bergmann M. et al. Echocardiographic. findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol 1988; 31: 26-30.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez-Vea A., Bardaji A., Garcia С. et al. Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kid Dis 1992; 19: 353-357.</mixed-citation><mixed-citation xml:lang="en">Martinez-Vea A., Bardaji A., Garcia С. et al. Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis. Am J Kid Dis 1992; 19: 353-357.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Fellner S.K., Lang R.M., Neumann A. et al. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 1993; 44: 1309-1315.</mixed-citation><mixed-citation xml:lang="en">Fellner S.K., Lang R.M., Neumann A. et al. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 1993; 44: 1309-1315.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Wizemann V., Schafer R., Kramer W. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 1993; 64: 202-206.</mixed-citation><mixed-citation xml:lang="en">Wizemann V., Schafer R., Kramer W. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 1993; 64: 202-206.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Silberberg J., Racine M., Barre P. et al. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4.</mixed-citation><mixed-citation xml:lang="en">Silberberg J., Racine M., Barre P. et al. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Pernandez A., Vega N., Jimenez F. et al. Effect of recombinant human erythropoietin treatment on hemodynamic parameters in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Nephrol 1992; 12: 207-211.</mixed-citation><mixed-citation xml:lang="en">Pernandez A., Vega N., Jimenez F. et al. Effect of recombinant human erythropoietin treatment on hemodynamic parameters in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Nephrol 1992; 12: 207-211.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Pascual J., Teruel J.L., Marcen R. et al. Hemodynamic and cardiac effects of erythropoietin in patients on regular dialysis. Int J Artif Organs 1992; 15: 349-353.</mixed-citation><mixed-citation xml:lang="en">Pascual J., Teruel J.L., Marcen R. et al. Hemodynamic and cardiac effects of erythropoietin in patients on regular dialysis. Int J Artif Organs 1992; 15: 349-353.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Zehnder С., Zuber M., Sulzer M. et al. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 1992; 61: 21-25.</mixed-citation><mixed-citation xml:lang="en">Zehnder С., Zuber M., Sulzer M. et al. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 1992; 61: 21-25.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Goldberg N., Lundin P., Delano В. et al. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 1992;124: 424-427.</mixed-citation><mixed-citation xml:lang="en">Goldberg N., Lundin P., Delano В. et al. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 1992;124: 424-427.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Pascual J., Teruel J.L., Moya J.L. et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: 280-287.</mixed-citation><mixed-citation xml:lang="en">Pascual J., Teruel J.L., Moya J.L. et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: 280-287.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Monrad E.S., Hess О.М., Murakami T. et al. Time course of regression of left ventricular hypertrophy after aortic valve replacement. Circulation 1988; 77: 1345-1355.</mixed-citation><mixed-citation xml:lang="en">Monrad E.S., Hess О.М., Murakami T. et al. Time course of regression of left ventricular hypertrophy after aortic valve replacement. Circulation 1988; 77: 1345-1355.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Cannella G., Paoletti E., Delfineo R. et al. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993; 44: 881-886.</mixed-citation><mixed-citation xml:lang="en">Cannella G., Paoletti E., Delfineo R. et al. Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 1993; 44: 881-886.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Radermacher J., Koch K.M. Treatment of renal anemia by erythropoietin substitution-The effects on the cardiovascular system. Clin Nephrol 1995; 44: S56-S60.</mixed-citation><mixed-citation xml:lang="en">Radermacher J., Koch K.M. Treatment of renal anemia by erythropoietin substitution-The effects on the cardiovascular system. Clin Nephrol 1995; 44: S56-S60.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Potoles J., Torralbo A., Martin P. et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kid Dis 1997; 29: 541-548.</mixed-citation><mixed-citation xml:lang="en">Potoles J., Torralbo A., Martin P. et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kid Dis 1997; 29: 541-548.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Mann J.F.E. Hypertension and cardiovascular effects-long term safety and potential long-term benefits of r-HuEPO. Nephrol Dial Transplant 1995; 10: 80-84.</mixed-citation><mixed-citation xml:lang="en">Mann J.F.E. Hypertension and cardiovascular effects-long term safety and potential long-term benefits of r-HuEPO. Nephrol Dial Transplant 1995; 10: 80-84.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Raine A.E.G., Roger S.D. Effects of erythropoietin on blood pressure. Am J Kid Dis 1991; 18: 76-83.</mixed-citation><mixed-citation xml:lang="en">Raine A.E.G., Roger S.D. Effects of erythropoietin on blood pressure. Am J Kid Dis 1991; 18: 76-83.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Radermacher J., Koch K.M. Erythropoietin and Hypertension. In: Bauer C., Koch K.M., Scigalla P., Wieczorek L. eds. Erythropoietin-Molecular Physiology and Clinical Application. Marcel, Dekker, New York, Basel, Hong Kong: 1993; 129-150.</mixed-citation><mixed-citation xml:lang="en">Radermacher J., Koch K.M. Erythropoietin and Hypertension. In: Bauer C., Koch K.M., Scigalla P., Wieczorek L. eds. Erythropoietin-Molecular Physiology and Clinical Application. Marcel, Dekker, New York, Basel, Hong Kong: 1993; 129-150.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Touam M., Olivia J.P., Zingraff J. et al. Does intravenous erythropoietin lead to an immediate, transient increase in arterial blood pressure in dialysis patients? Nephron 1994; 67: 240-241.</mixed-citation><mixed-citation xml:lang="en">Touam M., Olivia J.P., Zingraff J. et al. Does intravenous erythropoietin lead to an immediate, transient increase in arterial blood pressure in dialysis patients? Nephron 1994; 67: 240-241.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Roger S.D., Grasty M.S., Baker L.R.I. et al. Effects of oxygen breathing and erythropoietin on hypoxic vasodilatation in uremic anemia. Kidney Int 1992; 42: 975-980.</mixed-citation><mixed-citation xml:lang="en">Roger S.D., Grasty M.S., Baker L.R.I. et al. Effects of oxygen breathing and erythropoietin on hypoxic vasodilatation in uremic anemia. Kidney Int 1992; 42: 975-980.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Heidenreich S., Rahn K.-H., Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991; 39: 259-265.</mixed-citation><mixed-citation xml:lang="en">Heidenreich S., Rahn K.-H., Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991; 39: 259-265.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Tsukada H., Ishimitsu Т., Ogawa Y. et al. Direct vasopressor effects of erythropoietin in genetically hypertensive rats. Life Sci 1993; 52: 1425-1434.</mixed-citation><mixed-citation xml:lang="en">Tsukada H., Ishimitsu Т., Ogawa Y. et al. Direct vasopressor effects of erythropoietin in genetically hypertensive rats. Life Sci 1993; 52: 1425-1434.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Carlini R.G., Dusso A.S., Obialo C.I. et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endo-thelial cells. Kidney Int 1993; 43: 1010-1014.</mixed-citation><mixed-citation xml:lang="en">Carlini R.G., Dusso A.S., Obialo C.I. et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endo-thelial cells. Kidney Int 1993; 43: 1010-1014.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Neusser M., Tepel M., Zidek W. Erythropoietin increases cyto-solic free calcium concentration vH vascular smooth muscle cells. Cardiovasc Res 1993; 27: 1233-1236.</mixed-citation><mixed-citation xml:lang="en">Neusser M., Tepel M., Zidek W. Erythropoietin increases cyto-solic free calcium concentration vH vascular smooth muscle cells. Cardiovasc Res 1993; 27: 1233-1236.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Katch К., Mizuno К., Hashimoto S. et al. Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue. Life Sci 1994; 54: PL253-PL259.</mixed-citation><mixed-citation xml:lang="en">Katch К., Mizuno К., Hashimoto S. et al. Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue. Life Sci 1994; 54: PL253-PL259.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Gogusev J., Zhu D.-L., Herembert T. et al. Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase С activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun 1994; 199: 977-983.</mixed-citation><mixed-citation xml:lang="en">Gogusev J., Zhu D.-L., Herembert T. et al. Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase С activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun 1994; 199: 977-983.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Haller H., Christel С., Dannenberg L. et al. Signal transduction of erythropoietin in endothelial cells. Kidney Int 1996; 50: 481-488.</mixed-citation><mixed-citation xml:lang="en">Haller H., Christel С., Dannenberg L. et al. Signal transduction of erythropoietin in endothelial cells. Kidney Int 1996; 50: 481-488.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Nissenson A.R., Besarab A., Bolton W.K. et al. Target haematocrit during erythropoietin therapy. Nephrol Dial Transplant 1997; 12: 1813-1816.</mixed-citation><mixed-citation xml:lang="en">Nissenson A.R., Besarab A., Bolton W.K. et al. Target haematocrit during erythropoietin therapy. Nephrol Dial Transplant 1997; 12: 1813-1816.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Eschbach J.W., Egrie J.C., Downing M.R. et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engi J Med 1987; 316: 73-78.</mixed-citation><mixed-citation xml:lang="en">Eschbach J.W., Egrie J.C., Downing M.R. et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engi J Med 1987; 316: 73-78.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Eckardt K.-U. Erythropoietin: oxygen-dependent control of erythropoiesis and its failure in renal disease. Nephron 1994; 67: 7-23.</mixed-citation><mixed-citation xml:lang="en">Eckardt K.-U. Erythropoietin: oxygen-dependent control of erythropoiesis and its failure in renal disease. Nephron 1994; 67: 7-23.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Canadian erythropoietin study group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 1990; 300: 573-578.</mixed-citation><mixed-citation xml:lang="en">Canadian erythropoietin study group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 1990; 300: 573-578.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Marrades R.M., Roca J., Campistol J.M. et al. Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure. J Clin Invest 1996; 97: 2092-2100.</mixed-citation><mixed-citation xml:lang="en">Marrades R.M., Roca J., Campistol J.M. et al. Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure. J Clin Invest 1996; 97: 2092-2100.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Moore G.E., Bertocci L.A., Painter P.L. 3 IP-magnetic resonance spectroscopy assessment of subnormal oxidative metabolism in skeletal muscle of renal failure patients. J Clin Invest 1993; 91: 420-424.</mixed-citation><mixed-citation xml:lang="en">Moore G.E., Bertocci L.A., Painter P.L. 3 IP-magnetic resonance spectroscopy assessment of subnormal oxidative metabolism in skeletal muscle of renal failure patients. J Clin Invest 1993; 91: 420-424.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">McMahon L.P., McKenna M.J., Sangkabutra T. et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 1999; in press.</mixed-citation><mixed-citation xml:lang="en">McMahon L.P., McKenna M.J., Sangkabutra T. et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 1999; in press.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Besarab A., Bolton K., Browne J.K. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N En gi J Med 1998; 339: 584-590.</mixed-citation><mixed-citation xml:lang="en">Besarab A., Bolton K., Browne J.K. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N En gi J Med 1998; 339: 584-590.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Macdougall I.С., Ritz E. The normal haematocrit trial in dialysis patients with cardiac disease: are we any the less confused about target haemoglobin? Nephrol Dial Transplant 1998; 13: 3030-3033.</mixed-citation><mixed-citation xml:lang="en">Macdougall I.С., Ritz E. The normal haematocrit trial in dialysis patients with cardiac disease: are we any the less confused about target haemoglobin? Nephrol Dial Transplant 1998; 13: 3030-3033.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
